FTC “Barrs” Firm From Anticompetitive Agreements
This article was originally published in The Pink Sheet Daily
Federal Trade Commission gets rare victory in settlement with Barr over charges that cash payment delayed entry of generic Ovcon.
You may also be interested in...
Payments to delay generic entry could be banned under pending legislation before Congress.
Commission settles charges against the brand drug maker related to generic Ovcon 35.
The high court denies the Federal Trade Commission’s petition to hear the case regarding issues raised by brand companies’ reverse payments to generic firms.